Jump to: What is Mounjaro? | How do you get a Mounjaro prescription in the UK? | Mounjaro vs other weight-loss medications | Mounjaro side effects | Is Mounjaro a magic pill? | Frequently asked questions | Take home message
Mounjaro (tirzepatide) costs between £179 and £349 in the UK, depending on your dose and whether you’re in your first month of treatment.
While online pharmacies provide the lowest upfront cost, research shows you’re more likely to maintain weight loss when developing healthy habits alongside medication.
Second Nature’s Mounjaro programme includes the medication plus support from registered dietitians, starting at £229 monthly (with £50 off your first month at any dose).
Important safety information: Mounjaro (tirzepatide) is a prescription-only medication for treating type 2 diabetes and managing obesity. This article is for informational purposes only. Always consult with your healthcare provider before starting any new medication, particularly if you have underlying health conditions.
What determines Mounjaro’s cost in the UK?
The price you’ll pay for Mounjaro depends on three key factors:
- Provider type: Online pharmacies (lower cost) vs comprehensive programmes with healthcare professionals (higher initial cost, better outcomes)
- Dosage level: Starting doses cost less than maintenance doses (2.5 mg to 15 mg range)
- Support included: Programmes with dietitian support and habit coaching cost more but show improved long-term results1
Your choice depends on both budget and whether you want professional support developing sustainable habits alongside medication.
Second Nature’s Mounjaro pricing structure
Our transparent pricing reflects the comprehensive support you receive:
- First month (any dose): £50 discount applied
- 2.5 mg: £229/month (£179 first month)
- 5 mg: £259/month
- 7.5 mg: £289/month
- 10 mg: £309/month
- 12.5 mg: £329/month
- 15 mg: £349/month
All prices include medication, delivery, and daily access to registered dietitians and nutritionists. No hidden fees or additional charges apply.
Mounjaro vs other weight-loss medications
Clinical trials show significant differences in effectiveness between available weight-loss medications2. Understanding these differences helps explain varying price points across treatments.
Mounjaro (tirzepatide) demonstrates the highest average weight loss in clinical trials, with participants losing 15-25% of body weight. This dual-action medication targets both GLP-1 and GIP receptors.
Wegovy (semaglutide) shows impressive results with 15-17% average weight loss. It works by mimicking the GLP-1 hormone.
Saxenda (liraglutide) produces more modest results, typically 5-10% weight loss. This earlier-generation GLP-1 medication requires daily injections.
Orlistat achieves around 3% weight loss by blocking fat absorption. While significantly cheaper, the results don’t compare to newer medications.
The superior effectiveness of Mounjaro may justify its premium cost for those seeking substantial weight loss results.
NHS funding for Mounjaro
Currently, the NHS funds Mounjaro for type 2 diabetes management but has limited availability for weight loss alone; although services are starting to provide the medication.
A recent NICE announcement confirmed Mounjaro will be available to approximately 250,000 people with obesity over three years3. Priority goes to those with the highest BMIs and obesity-related health conditions.
On the NHS, eligibility requires:
- BMI over 35 with weight-related health problems
- Meeting the definition of ‘greatest clinical need’
- Commitment to lifestyle intervention alongside medication
Most people seeking Mounjaro for weight loss will need private prescriptions for the foreseeable future.
What is Mounjaro?
Mounjaro contains tirzepatide, a dual-action medication mimicking two natural hormones: GLP-1 and GIP.
These hormones work together to:
- Reduce appetite by communicating with your brain’s hunger centre
- Slow stomach emptying, helping you feel fuller longer
- Improve blood sugar control and insulin function
- Support healthier fat storage patterns
Manufactured by Eli Lilly, Mounjaro is marketed as Zepbound for obesity in the US. The dual hormone action sets it apart from single-hormone medications like Wegovy.
How do you get a Mounjaro prescription in the UK?
Through Second Nature: You’ll need a BMI over 27 plus meeting additional eligibility criteria. Complete our health quiz to check if you qualify for our programme.
Through the NHS for type 2 diabetes: NICE criteria include4:
- Inadequate control with other medications
- BMI of 35+ with obesity complications
- Or lower BMI where insulin would cause occupational issues
Through the NHS for obesity: Very limited availability reserved for those with the greatest clinical need and a BMI of over 40.
Lower BMI thresholds apply for people from certain ethnic backgrounds, typically reduced by 2.5 kg/m².
Does Mounjaro have side effects?
Common side effects include nausea, constipation, vomiting, and diarrhoea. These typically occur during dose increases and usually improve with time.
Less common effects include tiredness and headaches. Most people find side effects manageable, though some may need to discontinue treatment.
Our registered dietitians provide specific guidance on managing side effects through dietary adjustments and timing strategies.
Is Mounjaro a magic pill?
Weight-loss medications work best combined with lifestyle changes. They provide a tool for change, not a complete solution.
Mounjaro helps by:
- Reducing ‘food noise’ and constant hunger
- Creating space to develop healthier habits
- Providing motivation through initial results
However, maintaining weight loss requires building sustainable habits. Our programme focuses on using medication as an opportunity to create lasting lifestyle changes.
Frequently asked questions about Mounjaro costs
How much does Mounjaro cost per month in the UK?
Mounjaro costs vary by provider and support level. Second Nature’s comprehensive programme ranges from £229-£349 monthly depending on dose, with £50 off your first month.
Online pharmacies may offer lower medication-only prices but lack the professional support proven to improve long-term outcomes.
Is Mounjaro available on the NHS for weight loss?
Very limited NHS availability exists for weight loss, restricted to approximately 250,000 people over three years5. Priority goes to those with highest BMIs and obesity-related conditions.
Most people seeking Mounjaro for weight loss need private prescriptions.
Why does Second Nature cost more than online pharmacies?
Our programme includes registered dietitians and nutritionists available five days per week, not just medication delivery.
Research shows comprehensive support significantly improves weight-loss maintenance6. While the initial cost is higher, the long-term value often proves superior.
How does Mounjaro compare to other weight-loss medications?
Clinical trials show Mounjaro produces the highest average weight loss (15-25% of body weight) compared to alternatives7.
This superior effectiveness may justify the higher cost for those seeking substantial, sustainable results.
What happens if I need to pause or stop treatment?
You can cancel anytime without penalty. Our focus on habit development helps maintain results even if you need to stop medication.
We also provide specific protocols for safely transitioning off Mounjaro when the time is right.
Take home message
Mounjaro costs in the UK range from £229-£349 monthly through Second Nature, with a £50 first-month discount at any dose.
While online pharmacies offer lower prices for medication alone, comprehensive programmes providing professional support may provide a better option for long-term weight maintenance.
Your choice depends on whether you prioritise the lowest upfront cost or investing in support that improves your chances of lasting success.
Consider not just the monthly price but the value of developing sustainable habits that support your health long after medication ends.
Second Nature's Mounjaro and Wegovy programmes
Second Nature provides Mounjaro or Wegovy as part of our Mounjaro and Wegovy weight-loss programmes.
Why choose Second Nature over other medication providers, assuming you're eligible?
Because peace of mind matters.
We've had the privilege of working with the NHS for over eight years, helping people across the UK take meaningful steps toward a healthier, happier life.
Our programmes are designed to meet people where they are, whether that means support with weight loss through compassionate one-to-one health coaching, or access to the latest weight-loss medications (like Mounjaro and Wegovy) delivered alongside expert care from a multidisciplinary team of doctors, psychologists, dietitians, and personal trainers.
At the heart of everything we do is a simple belief: real, lasting change comes from building better habits, not relying on quick fixes. We're here to support that change every step of the way.
With over a decade of experience, thousands of lives changed, and a long-standing record of delivering programmes used by the NHS, we believe we're the UK's most trusted weight-loss programme.
We hope to offer you something invaluable: peace of mind, and the support you need to take that first step.
References
- Richards, R., et al. (2025). A Remotely Delivered, Semaglutide-Supported Weight Management Program: 12-Month Outcomes. JMIR Formative Research, 9(1), e72577.
- Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216.
- National Institute for Health and Care Excellence. (2025). Tirzepatide for managing overweight and obesity (TA1026)
- National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes (TA924)
- NHS England. (2025). Implementation guidance for tirzepatide in obesity management
- Hall, K.D. & Kahan, S. (2018). Maintenance of Lost Weight and Long-Term Management of Obesity. Medical Clinics of North America, 102(1), 183-197.
- Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002.
